Media.Player

A novel diagnostic method and therapeutic treatment of acute pulmonary inflammation

Summary

Researchersat OSU have discovered a novel antibody that could constitute a new therapeuticmethod to restrict the pathogenesis of ALI/ARDS. In a clinically relevantanimal model of ALI, a novel monoclonal antibody discovered by the researcherssignificantly inhibits neutrophil influx into alveolar space. Becauseneutrophil inflammation is central to development of ALI, this antibody mayprove to be the therapeutic agent that is greatly needed for ALI/ARDS patients.Moreover, this anitibody could be used as a novel diagnostic marker forALI/ARDS. This is critical because current diagnosis of ALI/ARDS is performedby the presence of non-cardiogenic pulmonary edema and respiratory failure,which are non-specific measures subject to inter-observer variability.

Technology Benefits

·       Enables earlydetection of ALI/ARDS·       Novel treatmentmethod to reduce severity of ALI/ARDS

Technology Application

·       Quantitativediagnostic tool for ALI/ARDS·       Method oftreatment for ALI/ARDS·       Treatment forother inflammatory diseases, especially lung

Detailed Technology Description

None

*Abstract

None

*Background

Acute lung injury (ALI) and its severe form, acute respiratorydisease syndrome (ARDS), are life-threatening diseases with a variety ofcauses, including sepsis, trauma, and pneumonia. ALI and ARDS are characterizedby pulmonary endothelial and epithelial injury, and loss of the alveolarcapillary barrier with an influx of inflammatory cells. The incidence isestimated at 1.5 to 75 cases per 100,000 individuals and affects approximately190,000 Americans annually, with mortality rates ranging from 25% to 40%.  The current treatment approach to ALI/ARDSrelies on ventilator and cardiovascular support. However, In spite of thesetreatments, unacceptable morbidity and mortality remain in ALI/ARDS patients. Thereis a great need for novel pharmacological therapeutics that can help reduce themorbidity and permanent lung tissue damage associated with ALI/ARDS.

*Stage of Development

Proof of concept stage.

Country/Region

USA